Breast Cancer Therapeutics Market Is Expected to Be Worth US $16.21 Bn by 2023
Featuring a largely consolidated vendor landscape where the leading three companies, namely Astra Zeneca, F.Hoffmann-LaRocheLtd., and Novartis AG, collectively accounted for over 93% of the overall market in 2014, the global market for breast cancer therapeutics has remained tough for small players over the years, observes Transparency Market Research in a recent report. The scenario, however, is increasingly changing as the patents of a number of blockbuster drugs from these vendors have either already expired or are soon to expire,...
View full press release